Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Neuropharmacology. 2015 Dec 31;105:61–71. doi: 10.1016/j.neuropharm.2015.12.025

Figure 9. No effects of subchronic oxytocin or chronic risperidone treatment on marble-burying deficits in Grin1neo/neo mice.

Figure 9

The marble-burying assay was conducted 4-5 days following the end of the subchronic regimen of oxytocin or vehicle, or 7-8 days following a chronic risperidone (21 day; 2.0 mg/kg/day) regimen. Post-hoc tests were not conducted, due to number of zero scores in the Grin1neo/neo groups.